Puma Biotechnology, Inc.'s (NASDAQ:PBYI) US$24m market value fall may be overlooked by institutional investors after a year of 1.6% returns - Simply Wall St News
Puma Bio Stock: Still Worthy After Earnings Surprise (NASDAQ:PBYI) | Seeking Alpha
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News